Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
JAMA Dermatology · 01.05.2025 · 161 (5) · 555
DOI: 10.1001/jamadermatol.2025.0025 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.05.2025. Verfasst von Kylie A Fletcher und 17 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, Tennessee. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
This cohort study describes the morphologic classification, histopathologic characteristics, treatments, and outcomes of chronic cutaneous immune-related adverse events occurring in adjuvant or metastatic setting.
Autor:innen und Institutionen
- Vanderbilt University School of Medicine, Nashville, Tennessee.
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
- Department of Medical Oncology, Melanoma Institute of Australia, Sydney, New South Wales, Australia.
- Department of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York University School of Medicine, New York.
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
- Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
Zitieren
APA
Fletcher, K. A., Goodman, R. S., Lawless, A., Woodford, R., Fa'ak, F., Tipirneni, A., Patrinely, J. R., Yeoh, H. L., Rapisuwon, S., Haydon, A., Osman, I., Mehnert, J. M., Long, G. V., Sullivan, R. J., Carlino, M. S., Menzies, A. M., Dewan, A. K., & Johnson, D. B. (2025). Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors. JAMA Dermatology, 161(5), 555. https://doi.org/10.1001/jamadermatol.2025.0025
Vancouver
Fletcher KA, Goodman RS, Lawless A, Woodford R, Fa'ak F, Tipirneni A, et al. Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors. JAMA Dermatology. 2025;161(5):555. doi:10.1001/jamadermatol.2025.0025
BibTeX
@article{Fletcher2025,
author = {Fletcher, Kylie A and Goodman, Rachel S and Lawless, Aleigha and Woodford, Rachel and Fa'ak, Faisal and Tipirneni, Asha and Patrinely, J Randall and Yeoh, Hui Ling and Rapisuwon, Suthee and Haydon, Andrew and Osman, Iman and Mehnert, Janice M and Long, Georgina V and Sullivan, Ryan J and Carlino, Matteo S and Menzies, Alexander M and Dewan, Anna K and Johnson, Douglas B},
title = {Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors},
journal = {JAMA Dermatology},
year = {2025},
volume = {161},
number = {5},
pages = {555},
doi = {10.1001/jamadermatol.2025.0025}
}
EUVIMED